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Abstract
Background: National authorities have to follow the evolution of diabetes to implement public health policies. An
algorithm was developed to identify patients with treated type 2 diabetes and estimate its annual prevalence in
Luxembourg using health insurance claims when no diagnosis code is available.
Methods: The DIABECOLUX algorithm was based on patients’ age as well as type and number of hypoglycemic
agents reimbursed between 1995 and 2006. Algorithm validation was performed using the results of a national
study based on medical data. Sensitivity, specificity and predictive values were estimated.
Results: The sensitivity of the DIABECOLUX algorithm was found superior to 98.2%. Between 2000 and 2006,
22,178 patients were treated for diabetes in Luxembourg, among whom 21,068 for type 2 diabetes (95%). The
prevalence was estimated at 3.79% in 2006 and followed an increasing linear trend during the period. In 2005, the
prevalence was low for young age classes and increased rapidly from 40 to 70 for male and 80 for female,
reaching a peak of, respectively 17.0% and 14.3% before decreasing.
Conclusions: The DIABECOLUX algorithm is relevant to identify treated type 2 diabetes patients. It is reproducible
and should be transferable to every country using medico-administrative databases not including diagnosis codes.
Although undiagnosed patients and others with lifestyle recommendations only were not considered in this study,
this algorithm is a cheap and easy-to-use tool to inform health authorities. Further studies will use this tool with
the aim of improving the quality of health care dedicated to diabetic patients in Luxembourg.
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Background
Diabetes Mellitus is a chronic disease leading to life-
threatening complications.
Diabetic patients aged under 55 stratified by age and
sex have a median life expectancy of 7 years less than
that of non-diabetic ones [1]. The estimated prevalence
for all-age-group worldwide diabetic patients, given by
the World Health Organization is of 2.8% (171 million
patients) in 2000 and should grow to 4.4% (366 million)
in 2030 [2]. Follows the necessity to monitor the evolu-
tion of this disease and the healthcare resources dedi-
cated to it in order to implement relevant health
policies.
Type 1 and type 2 diabetes have different etiologies
and physiopathologies [3] requiring different treatment,
follow-up and prevention practices. Therefore, in order
to better inform health authorities to implement rele-
vant health policies, type 1 and type 2 diabetes have to
be distinguished, as suggested by Guttman et al. [4].
Data used to determine these policies are either based
on clinical information or on medico-administrative
data. Clinical data is collected on population samples
carrying risks of selection bias, using patients’ records,
biological samples or self-administered questionnaires.
This data collection is time-consuming and expensive,
and does not guarantee accurate and exhaustive data-
sets. Despite their limits, several studies have found that
administrative datasets were a useful source of informa-
tion for diabetes surveillance [4-6]. The distinction
between the two types of diabetes can be achieved either
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any medium, provided the original work is properly cited.by a physician’s diagnosis or by an epidemiological algo-
rithm [7].
The literature provides some epidemiological algo-
rithms based on administrative data [5,7,8]. Authors
used either age at diagnosis or diagnosis codes of dia-
betes. However, medico-administrative data does not
always include such medical information. This is the
case in some European countries, among them France
and Luxembourg. Luxembourg national authorities are
currently developing projects to implement public health
policies directed toward type 2 diabetes but no accurate
prevalence rates are repeatedly available for international
comparisons [9].
T h eo b j e c t i v e so ft h i ss t u dy were to develop a vali-
dated algorithm in order to detect treated diabetic
patients using health insurance claims and identify
patients with type 2 diabetes as well as to estimate the
annual prevalence of treated type 2 diabetes in
Luxembourg.
Methods
Design of the study
A 3-step epidemiological algorithm called DIABECO-
LUX algorithm was developed to identify patients with
treated diabetes and to distinguish type 2 diabetic
patients, using administrative reimbursement databases.
It was applied to the population residing in the Grand
Duchy of Luxembourg covered by the national health
insurance over the period 2000-2006.
Setting and data sources
The national health insurance of Luxembourg is a com-
pulsory regime, covering 95% of the resident population.
Its claim database is representative in terms of age and
sex of the whole population of Luxembourg [10]. For
practical reasons (storage space, processing time), a pre-
liminary step selected from the total population (N =
484,560) the exhaustive population, who has been reim-
bursed at least one hypoglycemic agent (Anatomical
Therapeutic Chemical (ATC) classification: A10) [11],
either per os or injectable (i.e. insulin), over 2000-2006
(N = 28,269). This preliminary selection, based on the
hypothesis that a treated diabetic patient had at least
one hypoglycemic agent reimbursed over the period,
included all the treated diabetic patients and allowed
more rapidity in the execution of the algorithm. Infor-
mation about reimbursed medical acts, consultations,
treatments, hospitalizations, biological analyses was pro-
vided for that period by the Inspection Générale de la
Sécurité Sociale (Ministry of the national health insur-
ance). Moreover, information about hypoglycemic treat-
ment during the period 1995-1999 was added to the
dataset for the selected population in order to check the
history of its diabetic status. Then datasets were crossed
with death certificate databases to check patients’ vital
status. Since all patients were given a 22-digit identifica-
tion number to ensure secured anonymization and that
the identity of the patients could not be retrieved by
database crossing, no ethical or data protection approval
was required.
Definition of treated diabetes
The definition of treated diabetic patients that was con-
sidered in this study finds its roots in the methodology
of the ENTRED study [12-14], a validated transversal
epidemiological study defining treated diabetic patients
as having at least three A10 reimbursements in the year,
to avoid false positive patients (prescription and diagno-
sis errors). Since the DIABECOLUX study was longitu-
dinal, the above definition was softened to take into
account the continuity of the treatment. Therefore, a
treated diabetic patient was defined as fulfilled at least
one of the following four criteria:
▪ Criterion 1: 3 deliveries (or more) of A10 per year,
for 2 years or more;
▪ Criterion 2: 3 deliveries of A10 (or more) for 1
year AND 2 deliveries per year, for 2 years or more;
▪ Criterion 3: 2 deliveries of A10 per year, for 3
years or more - to consider patients often abroad;
▪ Criterion 4: 3 deliveries of A10 (or more) for the
year of Death (X), OR the year X-1, OR 2005, OR
2006 - to consider the right truncation and include
the incident cases of the last years of the period.
Algorithm steps
The first step of the algorithm was divided into two
phases. Its aim was to identify the patients treated for
either type 1 or 2 diabetes between 2000 and 2006 in a
first phase and 1995-2006 in a second phase for patients
dead in the early 2000’s and not included in the first
phase.
The second step of the algorithm selected within the
diabetic population patients who received oral hypogly-
cemic agents (OHAs, ATC classification: A10B) over
1995-2006. The remaining patients only received insulin
(A10A) over that period.
To determine a threshold dividing type 1 and type 2
diabetic patients among the latter, a subpopulation (N =
229) treated with solely insulin after having received
OHAs over 1995-2006 was selected. The mean age (y)
of this subpopulation, on the year of treatment change,
was calculated at 66.3. The third step included patients
older than 66, the year of their first insulin delivery
between 1995 and 2006.
Patients included in the second and the third steps
constituted the DIABECOLUX population, considered
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2006.
Algorithm validity
The relevance and accuracy were checked for each step
of the algorithm. The sensitivity (SE), the specificity
(SPE) and the positive and negative predictive values
(PPV and NPV) of the process of distinction between
type 1 and type 2 diabetes were estimated. Since no
gold standard was available, the range of the possible
values of the real proportion of type 2 diabetic patients
(T2P) was estimated in the population treated for dia-
betes in Luxembourg. This range was based on the
characteristics of treated diabetic patients i.e. the esti-
mated proportion of type 2 diabetic patients by age
group, the mean age of patients at the time of transition
from OHA to solely insulin treatment (mean age = 66)
and the minimum age at the time of this transition (age
= 27). Since T2P was not homogeneous over the ages of
the diabetic population, it was decomposed for age
classes [0-27[; [27-66[ and [66-100]. A range of possible
values for the decomposed T2P was estimated. Ranges
of possible true and false positives and negatives were
therefore estimated for each age class based on the rela-
tive ranges of decomposed T2P and the extreme values
found in the algorithm (i.e. everybody wrongly or prop-
erly included), and then pooled to calculate the intervals
of SE, SPE, PPV and NPV. This process was applied to
various possible values of the global T2P. The algorithm
remained constant during this process.
Prevalence estimation
Patients were defined as having treated type 2 diabetes
each year since their first A10 delivery until the end of
the period or their death. Treated type 2 diabetes preva-
lence for year X was defined as the number of patients
treated for type 2 diabetes in X divided by the resident
population covered by the national health insurance on
31
st December of that year. Prevalence rates were esti-
mated for each year from 2000 to 2006. Prevalence rates
were not estimated for the 1995-1999 period, since data
was only available for patients treated between 2000 and
2006.
Intra-country validation was performed using as a
comparator the prevalence estimated in the ORISCAV-
LUX study [15,16]. This validated study is an observa-
tional cross-sectional study collecting data from biologi-
cal samples and self-administered questionnaires of a
sample of 1,432 subjects aged from 18 to 69. The ORIS-
CAV-LUX population was representative of the residing
population in Luxembourg (2001 census) in terms of
s e x ,a g ea n dr e s i d e n c ed i s t r i c t .S i n c ep r e v a l e n c ew a s
estimated for both type 1 and type 2 diabetes, type 2
diabetes prevalence was calculated using the proportion
of type 2 diabetic patients among the ENTRED popula-
tion, set at 92% [8]. To be comparable with ORISCAV-
LUX, DIABECOLUX prevalence was re-estimated on
the population aged from 18 to 69 years and projected
in 2008 from 2000-2006 data. The projection method
was a double exponential smoothing (with the lowest
Root Mean Square Error to minimize prediction errors)
since the observed trend was linear (R
2 = 0.96).
Finally, the prevalence by age class was estimated for
males and females for year 2005.
European comparisons
To compare the annual prevalence of type 2 diabetes in
Luxembourg with that of neighboring countries, a direct
age-standardized rate from the European Union 15-
country (EU15) population [17] was applied to Luxem-
bourg, Belgium [18] and France [19-21]. 2000-Eurostat
prevalence rates [22] had already been age-standardized
using the same method.
When both type 1 and 2 diabetes were considered in
European prevalence rates, the percentage of 92% was
applied as for ORISCAV-LUX prevalence.
Statistical procedures
A specific missing data analysis was performed to ana-
lyze data quality.
Standard descriptive statistics were used to analyze the
database. When appropriate, a 95% confidence interval
[95% CI] was provided.
Population selection, data cleaning and statistical ana-
lyses were performed using SAS
® 9.2. package.
Results
Figure 1 shows the DIABECOLUX algorithm applied to
the population of Luxembourg. Step 1 included all
the patients treated for diabetes in Luxembourg
(N = 22,178). The first phase of step 1 included 96.8%
(N = 21,468) of this population. Among those, 83.4%
met criterion 1, 7.8% for criterion 4, 5.3% for criterion
2 and 0.3% for criterion 3. Around 3% (N = 710) were
added in the second phase of step 1. Among the 22,178
patients treated for diabetes, step 2 selected 20,808
patients and step3 added 260 patients.
Consequently, the DIABECOLUX database was consti-
tuted by 21,068 patients (95% of the total population
treated for diabetes) residing in Luxembourg and
defined as treated for type 2 diabetes, for the 2000-2006
period. The number of patients in the initial exhaustive
population, in the population treated for diabetes and in
the population treated for type 2 diabetes, over the
2000-2006 period and for each year is presented in
Table 1.
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The missing data analysis revealed 100% of data avail-
able for all the variables used in the algorithm.
Among the 6,091 patients rejected in step 1, 92
(0.04%) had a hospital discharge of Diabetes Mellitus
(ICD10 classification: E10-E14) [21] during the period.
The proportion T2P was estimated between 92.8% and
96.7%. Varying T2P values, SE was always estimated
higher than 98.2%, SPE always higher than 63.5%, PPV
always higher than 97.7% and NPV always higher than
65.9% (Table 2).
For the intra-country validation, the prevalence pro-
jection of treated type 2 diabetes for 18 to 69 year-old
patients was estimated in 2008 at 3.5% [95% CI: 3.4-3.5]
vs. ORISCAV-LUX: 2.6% [95% CI: 2.0- 3.5]; for males
4.1% [95% CI: 4.1-4.2] vs. 3.2% [95% CI: 2.2-4.7]; and for
females 2.8% [95% CI: 2.7-2.8] vs. 2.0% [95% CI: 1.3-3.1].
Prevalence of treated type 2 diabetes
The prevalence of treated type 2 diabetes in Luxem-
bourg was estimated for the DIABECOLUX population
at 3.15% (N = 13,152) in 2000 increasing linearly to
Figure 1 The DIABECOLUX algorithm applied to Luxembourg. * with y determined by the local physicians’ practices and estimated at 66.3
years old in Luxembourg.
Table 1 Number of patients in the initial exhaustive population, in the population treated for diabetes and in the
population treated for type 2 diabetes in Luxembourg, over the 2000-2006 period and for each year
2000-2006 2000 2001 2002 2003 2004 2005 2006
Initial Population 484,560 418,182 424,037 428,457 433,424 439,628 444,783 450,000
Treated Diabetes 22,178 13,416 14,277 14,956 15,489 16,241 17,172 17,522
Treated Type 2 Diabetes 21,068 13,152 13,944 14,704 15,269 16,026 16,751 17,070
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increase of 3.2%. The age of the population ranged
between 12 and 100 (median age: 66) in 2000, remaining
constant over the period. There were 50.6% of males in
2000 and 53.5% in 2006.
The EU15 age-standardized Luxembourg prevalence
rates were estimated at 4.20% in 2004 and 4.64% [95%
CI: 4.52-4.77] in 2007, which was not significantly differ-
ent from Belgium (3.6% [95% CI: 2.7-5.2]) in 2004 and
slightly higher than France (4.50%) in 2007.
Male and female prevalence rates, age-standardized
over the EU15 population, had a linear (R
2 =0 . 9 9f o r
both) and increasing trend (Figure 2) over time. Preva-
lence rates were respectively 3.6% and 3.4% in 2000 and
increased during the period to reach respectively 4.6%
and 4.3% in 2006. The mean annual increase in the pre-
valence between 2000 and 2006 was estimated at 4.3%
for males and 4.2% for females (respectively 4.7% and
4.5% for the 2000-2005 period). For the 2000-2005 per-
iod, the mean annual increase in the EU15-age standar-
dized French prevalence was estimated at respectively
6.1% and 5.7%.
French and Luxembourg prevalence rates were found
significantly different for males and for females (p <
0.05), Luxembourg prevalence rates being higher in both
cases. Moreover, Luxembourg female and French male
prevalence rates were found not significantly different.
Prevalence rates according to ages were similar for
both males and females in 2005 (Figure 3). They were
low and stable until 40. From 40 to 80, prevalence rates
increased rapidly, with an increasing gap between males
and females. This gap reached a maximum of 4.1 points
for the 60-69 age class. An inflection was initiated in
both curves in the 60-69 age class, leading to a decrease
Table 2 Sensitivity (%) and Specificity (%) of the DIABECOLUX algorithm for various possible proportions (T2P) of type
2 diabetes in the diabetic population (%)
T2P
† TP
† TN
† T2P.
POPtot
(1-T2P).
POPtot
SE = TP/(T2P.
POPtot)
SPE = TN/((1-T2P).
POPtot)
PPV = TP/
Pos
NPV = TN/
Neg
Min:
92.8%
20,581 1,110 20,581 1,597 100 69.5 97.7 100
93% [20,581-
20,626]
[1,067-1,110] 20,626 1,552 [99.8-100] [68.7-71.5] [97.7-97.9] [96.1-100]
94% [20,581-
20,847]
[845-1,110] 20,847 1,331 [98.7-100] [63.5-83.4] [97.7-99.0] [76.1-100]
95% [21,036-
21,068]
[731-1,109] 21,069 1,109 [99.8-100] [65.9-100] [99.8-100] [65.9-99.9]
96% [21,063-
21,068]
[731-887] 21,291 887 [98.9-99.0] [82.4-100] 100 [65.9-79.9]
Max:
96.7%
21,068 [731-732] 21,446 732 98.2 [99.9-100] 100 65.9
T2P: Proportion of type 2 diabetes in the treated diabetic population; TP: True Positive; TN: True Negative; POPtot: Total diabetic population (POPtot = 22,178);
SE: Sensitivity; SPE: Specificity; PPV: Positive Predictive Value; Pos: Population included (Pos = 21,068); NPV: Negative Predictive Value; Neg: Population excluded
(Neg = 1,110).
† : pooled from age classes.
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Figure 2 Evolution of the prevalence of treated type 2
diabetes in Luxembourg by sex over the 2000-2006 period (N
= 21,068), age-standardized over the EU15 population.
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Figure 3 Prevalence of treated type 2 diabetes in Luxembourg
by age class and sex in 2005 (N = 16,288).
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years old for females (14.3%).
Discussion
The application of the algorithm selected 21,068 patients
treated for type 2 diabetes over the 2000-2006 period in
the population of Luxembourg. Prevalence rates esti-
mated from DIABECOLUX and ORISCAV-LUX [15,16]
were found not significantly different, thereby validating
the algorithm for the relative population. Aiming at
improving knowledge to implement and assess health
policies, this algorithm required both good sensitivity
and a positive predictive value to identify type 2 diabetic
patients among treated diabetic population. They were
found respectively superior to 98.2% and 97.7% with a
specificity superior to 63.5%. To our knowledge, there is
no study about the sensitivity and the specificity con-
cerning similar algorithms in the literature.
It also appeared difficult to find comparable European
prevalence rates in the literature. Most studies did not
provide EU15 age-standardized data or enough details
to standardize data. Unfortunately, studies with age-
standardized prevalence rates used different methodolo-
gies in terms of population samples or data collection
[9,23-25]. Therefore, the final choice regarding European
comparisons was directed towards official data.
The EU15-age-standardized prevalence in Luxem-
bourg was 3.5% in 2000, close to that in its neighboring
countries (France: 3.0%, Belgium: 3.2%, Netherlands:
3.5%, Germany: 4.0%) [22] and not significantly different
from Belgium in 2004. French and projected Luxem-
bourg prevalence rates in 2007 were found to be very
close.
Since the prevalence rates provided in the literature
involved both type 1 and 2 diabetes, the proportion of
type 2 in the diabetic population, which stands at 92% as
estimated by ENTRED, had to be applied. This percen-
tage was estimated at 90% by WHO [26] and 95% by the
Ng-Dasgupta-Jonhson algorithm [7]. The DIABECOLUX
algorithm estimated it at 95%. Applying 95% to preva-
lence rates did not change the results of comparisons.
As a comparison, both French [20] and Luxembourg
prevalence rates (EU15 age-standardized) increased line-
arly over 2000-2005 with a greater mean annual increase
in prevalence for France for both genders. This can be
the result of the screening campaigns implemented in
France during this period. Moreover, the Luxembourg
prevalence was found significantly higher than the
French one for both genders. However, this gap is less
obvious for regions bordering Luxembourg [27,28].
After comparison of prevalence rates for France and
Luxembourg in 2005 by age and sex, no significant dif-
ference was found for male until 80 and female until 60.
Over 80, French prevalence rates decreased more
rapidly, which could be explained by a greater incidence
of treated patients in Luxembourg.
S i n c en op u b l i s h e dd a t ao nd iabetes is available for
Luxembourg [9], this tool can generate some and can
help policy-makers to follow the trend of this pathology.
Focusing on the database and algorithm limitations,
only diagnosed patients who are treated and reimbursed
were considered in this study. Undiagnosed patients and
t h o s eo n l yu n d e rl i f e s t y l er ecommendations were esti-
mated at 1.5% of the 18-69 year-old diabetic patients in
Luxembourg in 2008 [16]. Drugs brought abroad cannot
be identified in the database used. However, the induced
underestimation of the prevalence is negligible (high
reimbursement rate and residing population). Using
longitudinal data allowed avoiding prescription errors.
Finally, declaration for drug reimbursement being auto-
matically done by pharmacists limited the risk of errors.
The definition of a diabetic patient was based on the
number of A10 deliveries, since the diagnosis code was
not available in the claim database of Luxembourg and
hospital discharge codes were not always valid or accu-
rate. As in Guttmann et al. study [4], where the biggest
sum of sensitivity and specificity was for 3 claims, it was
set at 3 deliveries per year to limit prescription errors.
This restriction was relaxed to 2 deliveries for at least 3
years to include subjects who often travel abroad.
Finally, the algorithm misclassifies all type 1 diabetic
patients over 66, by wrongly categorizing a maximum of
260 patients under the ‘type 2 diabetes’ category. How-
ever, since the proportion of type 1 is low and the com-
plications and prevention policies are similar in this age
class, the impact of this misclassification is limited.
The DIABECOLUX algorithm was based on determi-
nistic conditions leading to the reproducibility of the
results and the possibility to be applied every year. Since
the mean age (y) of the solely insulin treatment start (i.
e. 66 in the population of Luxembourg) was based on
national medical practices and not determined by a
fixed threshold, it allows the transferability of the DIA-
BECOLUX algorithm to other countries.
Conclusion
The DIABECOLUX algorithm was developed to distin-
guish type 2 diabetes patients using medico-administra-
tive data. Validated by medical data in Luxembourg, it
appears to be a good tool to estimate the prevalence of
treated diabetes type 2 with a sensitivity and a positive
predictive value respectively greater than 98.2% and
97.7%. This algorithm is reproducible and should be
transferable to every country using medico-administra-
tive data, presenting an advantage in terms of costs of
data collection. It is a useful tool for health authorities
to follow the evolution of type 2 diabetes and evaluate
health policies.
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cares dedicated to type 2 diabetic patients in Luxem-
bourg with regard to European guidelines.
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